Florence, March 16th, 2016

The Menarini Group announces the founding of VaxYnethic, a joint venture between Menarini NewTech and BiosYnth, pioneer company operating in the field of technologies for the production of conjugated vaccines.

VaxYnethic, taking full advantage of the technological know how of BiosYnth and Menarini, will be engaged in a medium to long term research project on an innovative technological platform for the production of biopharmaceuticals. The objective of the project is to work on a new technology which will allow researchers to expedite the production processes of biopharmaceuticals, as well as co-operate with other market players in order to reduce the manufacturing time for vaccines and satisfy the ever growing demand on a worldwide scale.

Menarini’s interest in high technology is not new. In 2013 The Menarini Group acquired the Silicon Biosystems Menarini start up, a company which operates in the field of personalised medicine and holder of the patent on the DEPArray™ system which allows researchers to carry out a precise analysis of rare tumour cells. Later, in 2014, Menarini Biomarkers was founded, a company which currently conducts research projects on new biomarkers for the development of personalised medicine with the support of the DEPArray™ system.

 “We are very pleased to announce the founding of VaxYnethic through which we shall continue to project even more the company towards advanced technologies. BiosYnth and Menarini are two Italian companies, Tuscan even, whose technologies complement one another. This is an important sign of our country’s dynamism” declared Lucia Aleotti and Alberto Giovanni Aleotti, Chairman and Vice Chairman of The Menarini Group respectively.

 “The founding of VaxYnethic is an all-Italian project which shall be fully dedicated to the field of biopharmaceuticals. The synergy established between BiosYnth and the Menarini Group shall allow us to explore with the support of a broad technological platform, new scientific aspects related to poly-vaccinology and poly-pharmacology. This is a great opportunity for all of us and it represents the result of the continuous evolution in technology which has progressed through time in such a way as to be applied to complementary sectors within the biopharmaceutical field. This new initiative has also been made possible thanks to another Italian company, the Azimut Global Counseling, which initially brought the two companies together through the ‘Libera Impresa’ project and which, right from the start, believed in the benefits deriving from the complementary nature of the two companies which today go into making this joint venture”, commented Massimo Porro, Chairman of BiosYnth and new CEO of VaxYnethic.